Epichem runs on knife edge. It either makes a hundred or so thousand or loses it. Its not a huge revenue maker for PAA by any means. The majority of Epichems employees are PhD qualified so to not turn a huge profit is bad. They also have a risky business model with the majority of their income coming from on client (DNDi). If they pull funding Epichem will be in the crapper.
The market cap of PAA reflect that Epichem is worth $1mill at best and PAA dont really have anything else but IP. How do you value IP...by potential. Also some if the drugs PAA are developing are already approved for other treatment so how are they going to make any money from them. They can patent the novel application but they cant charge a premium for the product because people will just buy the cheapest option. So does the market think PAA will actually develop a drug...I very much doubt it but thats only my opinion.
Epichem, page-54
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |